INTEGRATED BIOPHARMA INC
For the period ended Oct 28, 2026. Filed Oct 28, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Oct 28, 2026 · Filed Oct 28, 2026
Use the contents to explore the available documents and sections.
Contents
Pay Versus Performance Table
| Year(1) | Summary Compensation Total For PEO($)(2) | Compensation Actually Paid to PEO ($)(3) | Average Summary Compensation for Non-PEO Named Executive Officers ($)(2) | Average Compensation Actually Paid to Non-PEO Named Executive Officers ($)(3) | Value of Initial Fixed $100 Investment Based on Total Shareholder Return ($)(4) | Net Income (loss) ($)(in thousands)(5) |
|---|---|---|---|---|---|---|
| 2026 | $350,732 | $349,208 | $360,744 | $364,100 | $34 | $(2,842) |
| 2025 | 325,037 | 318,641 | 334,577 | 333,380 | 72 | 808 |
| 2024 | 331,301 | 315,189 | 343,719 | 328,805 | 42 | 112 |
(1) For the Fiscal Year Ended June 30.
(2) The Company’s Principal Executive Officer (“PEO”) are the Co-Chief Executive Officers, amount represents the amounts per the Summary Compensation Table Total for each of the Co-CEO’s and the Company’s only Non-PEO is its Chief Financial Officer and Senior Vice President.
(3) Compensation Actually Paid was adjusted for changes in the estimated fair value of equity awards in accordance with Item (402(v) of Regulation S-K. Accordingly, the options awards disclosed in the Summary Compensation Table were deducted and the estimated fair value of any equity awards granted in the fiscal year were added and changes in fair value for vested and unvested awards from the previous fiscal year were either added or subtracted.
(4) Calculated pursuant to Item 201(e) of Regulation S-K.
(5) Net income (loss) for each of the fiscal year ended June 30.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.